Immunological and clinical implications of immune checkpoint blockade in human cancer

Cited 4 time in webofscience Cited 0 time in scopus
  • Hit : 98
  • Download : 0
Immune checkpoint inhibitors (ICIs) such as anti-PD-1 and anti-CTLA-4 therapy are now FDA-approved treatment options for different cancer types. However, the therapeutic efficacy of ICIs varies substantially among cancer types and patients, and only a limited proportion of cancer patients benefit clinically from ICIs. To improve the therapeutic efficacy of cancer treatments involving ICI, the mechanisms of response to ICIs and the heterogeneous pattern of immune checkpoint receptor expression need to be better understood. Here, we review recent studies on ICIs in human cancer, providing the necessary basis for the rational design of immunotherapy and for appropriate patient selection.
Publisher
PHARMACEUTICAL SOC KOREA
Issue Date
2019-07
Language
English
Article Type
Review
Citation

ARCHIVES OF PHARMACAL RESEARCH, v.42, no.7, pp.567 - 581

ISSN
0253-6269
DOI
10.1007/s12272-019-01140-1
URI
http://hdl.handle.net/10203/263227
Appears in Collection
MSE-Journal Papers(저널논문)
Files in This Item
There are no files associated with this item.
This item is cited by other documents in WoS
⊙ Detail Information in WoSⓡ Click to see webofscience_button
⊙ Cited 4 items in WoS Click to see citing articles in records_button

qr_code

  • mendeley

    citeulike


rss_1.0 rss_2.0 atom_1.0